Stem Cell Bahamas

07/03/2019

ENDOVASC
HIGHLIGHTS DIABETES AND CARDIOVASCULAR DISEASE
Vol 3

ENDOVASC is an monthly Highlights, providing a platform for advances in translational and clinical research. Our aims to re-publish original research, review articles and short communications from High Impact Medicals Journals about information in Diabetes and Cardiovascular Disease.

CARDIOVASCULAR DISEASE
Endovascular vs Open Repair of Intact Descending Thoracic Aortic Aneurysms
This retrospective study used Medicare data to compare outcomes of patients who underwent open surgical repair or thoracic endovascular aortic repair (TEVAR) to manage intact descending thoracic aortic aneurysms. Propensity score matching was used to create a group of 2470 TEVAR patients and a group of 1235 open surgical repair patients for analysis. The median follow-up was 4.7 and 5.6 years for TEVAR and open surgical repair, respectively. TEVAR was associated with a lower odds of perioperative mortality compared with open surgical repair using logistic regression. However, open surgical repair was associated with lower risk of reintervention at 9 years compared with TEVAR. Because of its association with better perioperative mortality risk and survival outcomes up to 9 years post surgery, the authors suggest considering TEVAR as the first-line intervention for intact descending thoracic aortic aneurysms even though results may not be as durable as those associated with open surgical repair. DOI: 10.1016/j.jacc.2018.10.086

Risk of Cardiac and Sudden Death Higher Without Revascularisation of a Coronary Chronic Total Occlusion
Patients who underwent a coronary chronic total occlusion (CTO) percutaneous coronary intervention (PCI) attempt were followed for a median of 6 years to compare outcomes in those with successful revascularization (CTO-R group) with outcomes in those not revascularized (CTO-NR group). The risk of cardiac death and sudden cardiac death (SCD) and/or sustained ventricular arrhythmias (SVAs) was significantly higher in the CTO-NR group compared with the CTO-R group. This was driven mainly by an increased risk of cardiac death and SCD/SVA in the subgroup of infarct-related artery (IRA) CTO patients. Patients with CTO without successful revascularization at PCI have a significantly increased risk of cardiac death and SCD/SVA compared with those with CTO revascularized. IRA CTO patients without revascularization are at the highest risk of adverse outcomes.

Metformin Use and Cardiovascular Events in Patients With Type 2 Diabetes and Chronic Kidney Disease
Patients with diabetes and chronic kidney disease (CKD) were followed to compare outcomes in metformin users and non-users. Metformin users had lower overall mortality rates, cardiovascular mortality rates, and rates of cardiovascular events compared with non-users. The rate of end-stage renal disease (ESRD) was 4.0% among metformin users versus 3.6% in non-users, but there was no significant association between metformin use and the risk of ESRD. Metformin use showed independent associations with a reduced risk of all-cause mortality, cardiovascular death, cardiovascular events, and the kidney disease composite of ESRD and death. In patients with stage 3 kidney disease, metformin use may be safe and may reduce the risk of mortality and cardiovascular events. https://doi.org/10.1111/dom.13642



ENDOVASC
NASSAU BAHAMAS

30/01/2019

https://www.emc2.foundation/science-blog/2019/1/14/first-annual-einsteinium-awards-winners

We are happy because our company won a very important award in US!! Move forward, this is the right way!!

14/01/2019

ENDOVASC
HIGHLIGHTS DIABETES AND CARDIOVASCULAR DISEASE
Vol 2

ENDOVASC is an monthly Highlights, providing a platform for advances in translational and clinical research. Our aims to re-publish original research, review articles and short communications from High Impact Medicals Journals about information in Diabetes and Cardiovascular Disease.

CARDIOVASCULAR DISEASE
Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease - The EUCLID Trial
This study of patients with symptomatic peripheral artery disease (PAD; N = 13,885) evaluated the association between diabetes and a composite of major adverse cardiovascular events (MACE). MACE occurred in 15.9% of patients with comorbid diabetes compared with 10.4% of patients without diabetes. There was a 14.2% increase in MACE risk with every 1% increase in HbA1c. Patients with PAD and comorbid diabetes are at significantly higher risk for cardiovascular and limb ischemic events compared with nondiabetic patients with PAD.
http://www.onlinejacc.org/content/72/25/3274

CARDIOVASCULAR DISEASE
Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis: Analysis from a Stratified Multicenter Randomized Trial
This study is an analysis of a subgroup of 391 patients who were randomized to treatment using pharmaco mechanical catheter-directed thrombosis (PCDT) with anticoagulation or anticoagulation alone (No-PCDT) for acute iliofemoral deep vein thrombosis (DVT) as part of the large, multicenter ATTRACT trial. Although the occurrence of post-thrombotic syndrome (PTS) was similar between the groups over a 24-month follow-up, there was lower PTS severity in the PCDT group. Patients treated with PCDT also had greater reductions from baseline in leg pain and swelling at 10 and 30 days and lower mean VCSS at all 6-month intervals (6, 12, 18, and 24 months after PCDT). Although general quality of life was equivalent between the treatment groups, venous disease–specific quality of life improved significantly more in those in the PCDT group compared with the No-PCDT group. Although further study is necessary to make stronger recommendations, these data suggests that PCDT may be beneficial in reducing PTS severity and leg pain in patients with acute iliofemoral DVT.
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.037425

DIABETES
Clinical, Quality-of-Life, and Cost Associated With Glycemic Control in Type 1 Diabetes
The authors evaluated the quality of life (QoL) and costs associated with outcomes of the Diabetes Control and Complications Trial (DCCT) in patients who maintained excellent vs poor glycemic control over a period of 30 years. A decrease in the incidence of several complications was observed over 30 years (retinopathy, 45% to 5%; end-stage renal disease, 5% to 0%; clinical neuropathy, 50% to 15%; myocardial infarction, 5% to 3%; stroke, 2% to 0.4%; and death, 20% to 6%). Quality-adjusted life-years increased by approximately 1.62, resulting in savings of approximately $90,900 per patient. This study reveals how excellent glycemic control can vastly improve a patient's QoL through the reduction of complications, comorbidities, and death.
What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes?

09/01/2019

Stem Cell Bahamas is the option for many patients with immune diseases. Call us!!!

Stem cell transplant now in trials for rebooting immune system

29/12/2018

Dear Friends,
One of the Institutional objectives of
Stem Cell Bahamas is to disseminate knowledge from scientific evidence published in high impact medical journals but in an easy and understandable language for the population in general. Much is published but little to the society, that is hungry for knowledge, is transmitted. This group is the perfect place to exchange ideas, opinions, questions or comments. For Stem Cell Bahamas it will be a pleasure to answer or channel these concerns. Regenerative and personalized medicine is already among us. Regards!!!

21/12/2018

NO HYPOGLYCAEMIA. Transplantation of bone marrow stem cells decreases tissue inflammation, activates tissue stem cells and regenerates insulin-secreting cells in diabetic patients. But they also activate and regenerate the GLUCAGON secreting cells. This explains that patients do not have episodes of hypoglycaemia after bone marrow transplant. No more severe hyperglycemia, no more hypoglycaemia and significant improvement of the quality of life.

18/12/2018

ENDOVASC
HIGHLIGHTS DIABETES AND CARDIOVASCULAR DISEASE

ENDOVASC is an monthly Highlights, providing a platform for advances in translational and clinical research. Our aims to re-publish original research, review articles and short communications from High Impact Medicals Journals about information in Diabetes and Cardiovascular Disease.

DIABETES
Over the first decade of this millennium, the rates of nontraumatic lower-extremity amputation (NLEA) decreased by 43% across the US. However, recently we published a report that used serial cross-sectional data from national databases and showed that, since 2009, the rates of NLEA in people with diabetes have increased, whereas, for those without diabetes, the rates have continued to decrease.
care.diabetesjournals.org/content/early/2018/11/05/dc18-1380

DIABETES
Diabetic neuropathy (DN) is a potentially debilitating and financially costly complication of type 1 diabetes (T1D). Two of the most prevalent types of diabetic neuropathy are diabetic sensorimotor polyneuropathy (DSPN) and cardiovascular autonomic neuropathy (CAN). While the prevalence of DN in younger patients is lower than in adults, studies have reported numbers as high as 7% in young patients.
www.liebertpub.com/doi/10.1089/dia.2018.0249

STROKE
Patients with ischemic stroke assessed with computed tomography (CT) at presentation and after 24 hours and undergoing successful endovascular recanalization were followed to compare the lesion growth from imaging to revascularization in patients with hyperacute versus acute presentation.
https://www.ahajournals.org/doi/10.1161/STROKEAHA.118.023457

ENDOVASC
NASSAU BAHAMAS

23/11/2018

Resurgence of Diabetes-Related Nontraumatic Lower Extremity Amputation in the Young and Middle-Aged Adult U.S. Population
Linda S. Geiss, Yanfeng Li, Israel Hora, Ann Albright, Deborah Rolka, Edward W.Gregg
Diabetes Care Nov 2018,
Age-adjusted NLEA rates per 1,000 adults with diabetes decreased 43% between 2000 (5.38 [95% CI 4.93-5.84]) and 2009 (3.07 [95% CI 2.79-3.34]) (P < 0.001) and then rebounded by 50% between 2009 and 2015 (4.62 [95% CI 4.25-5.00]) (P < 0.001). In contrast, age-adjusted NLEA rates per 1,000 adults without diabetes decreased 22%, from 0.23 per 1,000 (95% CI 0.22-0.25) in 2000 to 0.18 per 1,000 (95% CI 0.17-0.18) in 2015 (P < 0.001). The increase in diabetes-related NLEA rates between 2009 and 2015 was driven by a 62% increase in the rate of minor amputations (from 2.03 [95% CI 1.83-2.22] to 3.29 [95% CI 3.01-3.57], P < 0.001) and a smaller, but also statistically significant, 29% increase in major NLEAs (from 1.04 [95% CI 0.94-1.13] to 1.34 [95% CI 1.22-1.45]). The increases in rates of total, major, and minor amputations were most pronounced in young (age 18-44 years) and middle-aged (age 45-64 years) adults and more pronounced in men than women.
CONCLUSIONS
After a two-decade decline in lower extremity amputations, the U.S. may now be experiencing a reversal in the progress particularly in young and middle-aged adults.

06/11/2018

Meeting of researchers and others important projects in Chicago. Beautiful city!!!!

20/10/2018

Type 1 diabetes, like other autoimmune diseases, has no cure yet. But complete remission and normal quality of life are achieved with the autologous bone marrow stem cell transplant. Clinical option validated by scientific evidence, safety, effectiveness and ease to perform.

15/09/2018

Bone Marrow Stem Cells Transplant in Diabetic Patient is our option for you. The focus is to have confidence in your own cells, not immunosuppression or cell cultures. Call us for more information.